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[LETTER TO THE EDITOR /Digestive
Glubran2®, Histoacryl® or Truﬁll®:
Which cyanoacrylate glue for
endovascular use?
We  read  with  great  interest  the  article  by  Won  et  al.
[1]  published  recently  in  Diagnostic  and  Interventional
Imaging  and  reporting  effectiveness  of  transcatheter  arte-
rial  embolization  (TAE)  using  N-butyl  cyanoacrylate  (NBCA)
in  selected  patients  with  visceral  artery  pseudoaneurysms
(PAs).  We  have  several  comments.  First  of  all,  we  would
like  to  congratulate  the  authors  for  their  study,  which  rep-
resents  one  of  the  main  series  to  date  reporting  results
on  TAE  with  NBCA  glue  as  an  embolic  agent  in  such  a  set-
ting.  Recently,  TAE  has  generated  considerable  interest  as
the  ﬁrst-line  treatment  for  PAs.  The  success  rate  is  high,
ranging  from  62  to  100%  in  visceral  PAs,  and  the  morbidity
and  mortality  rates  are  low  [2—4].  Most  investigators  agree
that  coils  are  the  most  appropriate  embolic  material  [2].
The  present  study  shows  that  embolization  using  NBCA  as
the  sole  embolic  agent  is  a  safe  and  effective  technique
for  treatment  of  visceral  PAs  in  various  locations.  We  abso-
lutely  agree  with  the  authors  about  efﬁcacy  and  safety  of
glue  embolization  of  the  vessel  supplying  the  PA.  We  ﬁnd
the  use  of  NBCA  particularly  interesting,  especially  in  hemo-
dynamically  unstable  bleeding  patients  and  in  patients  with
underlying  coagulopathy,  because  it  provides  faster  and  bet-
ter  hemostasis  than  other  embolic  agents.  In  addition,  glue
may  reach  distal  targets  in  tortuous  vessels  that  cannot  be
navigated  with  microcatheters.  In  our  institution,  TAE  using
NBCA  as  the  only  embolic  agent  has  also  become  the  salvage
treatment  of  choice  in  this  indication,  whenever  patency  of
the  parent  vessel  may  be  compromised.  However,  we  would
like  to  stress  the  fact  that  few  glues  are  ofﬁcially  available
on  the  market  worldwide  for  endovascular  use:  Glubran2®
(GEM,  Viareggio,  Italy)  and  Truﬁll® (Cordis,  Miami  Lakes,
FL)  which  have  CE  marking  and  FDA  approval,  respectively
[4].  Histoacryl® (B/Braun,  Tuttlingen,  Germany),  which  was
used  in  the  present  study  as  in  many  previous  series,  is  nor-
mally  not  allowed  for  endovascular  purpose  because  of  the
absence  of  CE  marking  and  FDA  approval.  Its  use  is  consid-
ered  as  off-label  in  such  a  setting.  Furthermore,  Histoacryl®
polymerises  faster  than  other  glues  resulting  in  more  chal-
lenging  use  [5].  Regarding  authorized  glues,  Glubran2® is
now  a  well-known  surgical  glue  in  which  NBCA  is  combined
with  another  monomer,  metacryloxysulpholane,  to  produce
a  more  pliable  and  stable  polymer  whose  milder  exothermic
reaction  (45 ◦C)  results  in  less  inﬂammation  and  histotoxic-
ity  than  Histoacryl® or  Truﬁll ® [5].  Lastly,  Glubran2® has  the
advantages  of  being  very  cheap  by  comparison  with  Truﬁll®
h
2
Eabout  100D versus  2000$  per  1  mL  vial)  and  more  available
orldwide;  Truﬁll® being  used  only  in  the  US.
In  conclusion,  our  experience  and  data  from  recent
iterature  suggest  that  TAE  using  cyanoacrylate  glue  in  well-
rained  hands  could  be  more  effective  in  controlling  the
leeding  from  visceral  artery  pseudo-aneurysms  than  other
mbolic  agents  if  used  with  great  caution.  NBCA  may  be
peciﬁcally  useful  in  the  setting  of  hemodynamic  instability,
oagulopathy,  and  narrowed  vessels  that  are  not  amenable
o  distal  embolization  by  microcoils.  However,  only  the
se  of  authorized  glues  should  be  the  rule.  Furthermore,
BCA  embolization  should  absolutely  not  be  attempted  for
As  located  at  the  proximal  level  of  major  visceral  arteries
ecause  of  the  risk  of  ischemic  complications  and  end-organ
amage.
isclosure  of  interest
he  author  declares  that  he  has  no  conﬂicts  of  interest  con-
erning  this  article.
eferences
1] Won Y, Lee SL, Kim Y, Ku YM. Clinical efﬁcacy of transcatheter
embolization of visceral artery pseudoaneurysms using N-butyl
cyanoacrylate (NBCA). Diagn Interv Imaging 2015;96:563—9.
2] Loffroy R, Guiu B, Cercueil JP, et al. Transcatheter arterial
embolization of splenic artery aneurysms and pseudoaneurysms:
short- and long-term results. Ann Vasc Surg 2008;22:618—26.
3] Song HH, Won YD, Kim YJ. Transcatheter N-butyl cyanoacry-
late embolization of pseudoaneurysms. J Vasc Interv Radiol
2010;21:1508—11.
4] Tokuda T, Tanigawa N, Shomura Y, et al. Transcatheter emboliza-
tion for peripheral pseudoaneurysms with N-butyl cyanoacry-
late. Minim Invasive Ther Allied Technol 2009;18:361—5.
5] Loffroy R, Guiu B, Cercueil JP, Krausé D. Endovascular ther-
apeutic embolisation: an overview of occluding agents and
their effects on embolised tissues. Curr Vasc Pharmacol
2009;7:250—63.
R.  Loffroy
Department of Vascular, Oncologic and
Interventional Radiology, Le2i, UMR  CNRS 6306,
University of Dijon School of Medicine, Bocage
Teaching Hospital, 14, rue Paul-Gaffarel, BP
77908, 21079 Dijon cedex, France
E-mail address: romaric.loffroy@chu-dijon.frttp://dx.doi.org/10.1016/j.diii.2015.04.011
211-5684/© 2015 Éditions franc¸aises de radiologie. Publié par
lsevier Masson SAS. Tous droits réservés.
